Regulatory & Legal

City councillors, labour unions, and community groups plan a major counter-rally to defend Toronto's diversity against rising xenophobia and a protest.

A mysterious new political group has launched a billboard blitz targeting Donald Trump in key battleground districts, signaling an early start to the 2026 wars.

With a new board appointment and $19M in funding, Enhanced Genomics is leveraging its 3D genomics platform to build its own pipeline of precision therapies.

Facing economic fallout and service crises, over 1,900 municipal leaders will press provincial officials for concrete action at a critical conference.

With new funding, Major Medical Devices is advancing a novel AAA repair device that uses arm access, promising safer procedures and wider patient eligibility.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

After a year of scrutiny, a former Urban League leader invests in the aspiring minority-controlled stock exchange, validating its mission for structural change.

Health Canada uncovers counterfeit erectile dysfunction drugs in Mississauga, warning of life-threatening dangers and a compromised supply chain.

Over 450 elite runners from 50 nations converge on Apalachee Regional Park this Saturday, cementing Tallahassee's status as a world-class sports hub.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

A new report reveals 10 proven ways to fix the critical mental health gap for trafficking survivors, as 75% call it their most urgent need.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

Modest growth is forecast, but Canada's economy faces a pivotal year as federal stimulus clashes with looming CUSMA renegotiations and U.S. headwinds.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

A new study reveals the hidden quality-of-life toll of a common virus on transplant patients, highlighting the urgent need for targeted new therapies.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.